Previous 10 | Next 10 |
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44th Annual Healt...
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44 th Annual H...
2024-02-19 12:24:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapul...
Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, is reporting its Q3 2024 financial numbers as well as providing an update on the company. Notable numbers ...
2024-02-13 18:34:02 ET Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Conference Call February 13, 2024, 05:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief...
2024-02-13 17:04:03 ET More on VistaGen Therapeutics VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond Vistagen shares move up after Jefferies upgrade Seeking Alpha’s Quant Rating on VistaGen Therapeutics Historical earnings data for VistaG...
2024-02-13 16:33:22 ET More on VistaGen Therapeutics VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond Vistagen shares move up after Jefferies upgrade Seeking Alpha’s Quant Rating on VistaGen Therapeutics Historical earnings data for VistaG...
Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on track PALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical com...
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
2024-02-12 17:35:56 ET More on VistaGen Therapeutics VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond Vistagen shares move up after Jefferies upgrade Vistagen climbs as Stifel launches at Buy on anxiety prospects Seeking Alpha’s Quant Rati...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, is reporting positive results from a phase 2A pilot study of PH15, its investigati...
PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participants PH15 was safe and well-tolerated with an adverse event profile similar to placebo Vistagen (Nasdaq: VTGN),...